Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Veracyte Inc. Stories

2014-03-18 16:25:22

-- 88% Growth in Full-Year 2013 Revenue, 92% Growth in Year-Over-Year FNA Volume -- SOUTH SAN FRANCISCO, Calif., March 18, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results and business progress for the quarter and full year ended December 31, 2013, and provided financial guidance for 2014. Revenue was $6.8 million for the fourth quarter of 2013, an increase of 53%, compared to 2012 fourth quarter revenue of $4.5 million. Full-year 2013 revenue was $21.9...

2014-03-17 08:28:49

SOUTH SAN FRANCISCO, Calif., March 17, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A. Brooks joins the company as executive vice president, general counsel and secretary; and Andy Thorson joins as executive vice president, corporate strategy and business development. "I am thrilled to welcome Julie Brooks and Andy...

2014-03-11 08:29:14

SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress. The live webcast and subsequent replay may be accessed by visiting Veracyte's website...

2014-03-03 16:25:19

-- Presentation and Webcast Scheduled for Tuesday, March 4, at 8 a.m. ET -- SOUTH SAN FRANCISCO, Calif., March 3, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced a change in the company's presentation date and time at the Cowen and Company 34(th) Annual Health Care Conference. Bonnie H. Anderson, president and chief executive officer, will present on Tuesday, March 4, 2014 at 8:00 a.m. ET in the St. Botolph room at The Boston Marriott Copley Place in Boston, Mass....

2014-02-26 08:28:18

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Cowen and Company 34(th) Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m. ET in Boston, Mass. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to...

2014-02-05 08:28:49

SOUTH SAN FRANCISCO, Feb. 5, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to...

2013-12-16 16:25:49

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC). The new policy applies to approximately 13 million of Cigna's medical customers and is effective immediately. The Afirma GEC is used to...

2013-11-25 16:27:06

-- 3Q Revenue Reached $5.6 Million, Increasing 74% Compared to Prior Year -- SOUTH SAN FRANCISCO, Calif., Nov. 25, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2013, and provided an update on recent business progress. Revenue was $5.6 million for the third quarter of 2013, versus $3.2 million for the third quarter of 2012, an increase of 74%. Revenue for the first nine months of 2013 was $15.0 million, compared...

2013-11-13 08:29:25

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle aspiration (FNA) samples that are indeterminate and sub-classified as Hurthle cell neoplasms by cytopathology. The findings were presented in a poster session at the American Society of...

2013-11-11 08:28:10

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25, 2013. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The live webcast and subsequent replay may be accessed by visiting Veracyte's...